Introduction
In multiple myeloma (MM), the introduction of novel agents has improved the quality of response, especially after high dose chemotherapy followed by autologous stem cell transplantation (ASCT). The parameters defining the international uniform response criteria (IURC) are primarily monoclonal protein and bone marrow infiltration of myeloma cells (1) . However, since MRI studies in patients with MM have demonstrated that 18-50% of them present with focal lesions (FL) (2) (3) (4) , it is likely that unilateral biopsy of the iliac crest for histological and aspiration-based examinations misses accumulations of myeloma cells located elsewhere in the body.
A promising extension of the current diagnostic tools for assessment of tumour mass and treatment response is therefore the application of novel imaging techniques.
Whole body magnetic resonance imaging (wb-MRI) has been proven to be the best available imaging method to display bone marrow infiltration in patients with MM with regard to sensitivity and proportion of the body displayed (5-7). Wb-MRI is able to detect and to monitor tumour mass of MM independent of the secretory activity and the location of the malignant cells. In patients with monoclonal plasma cell disease, FLs and diffuse infiltration detected by MRI are significant prognostic markers for progression free and overall survival (8) (9) (10) (11) . Until now, it is not clear whether the assessment of remission can be matched with changes in MRI. Also, it has not yet been clarified if residual changes in bone marrow like FLs may be the source of relapse of disease. Therefore, the aim of the present study was to compare remission of disease with changes in wb-MRI and to investigate the prognostic significance of residual bone marrow infiltration.
Design and Methods

Patient cohort
We retrospectively evaluated a series of 100 consecutive patients with MM from a single institution who were examined with wb-MRI at the onset of therapy between October 2004 and July 2010 as well as 3 to 6 months after ASCT. Time between first MRI and initiation of systemic treatment was 0.4 months (range 0 -3.9) and between ASCT and second MRI 5.6 months (range 0.4 -39.3), respectively. The study group consisted of 58 males and 42 females with a median age of 58 years at first wb-MRI (range 28 -73). All patients underwent one (n=45) or two (n=55) cycles of front-line high-dose chemotherapy with melphalan 200 mg/m 2 followed by ASCT according to the protocols of the GMMG-HD3-or GMMG-HD4-trial or analogous protocols (12) .
For response assessment the IURC were used (1). To simplify, analysis modification of the criteria was as follows: IURC remission was determined summarising very good partial remission (VGPR) and partial remission (PR) as seroPR. Study approval was obtained from the institutional review board of the University of Heidelberg.
MRI-protocol and evaluation
All patients underwent an MRI-protocol as reported recently (5, 9) . No contrast medium was given. Number of FL as well as degree of diffuse infiltration before and after treatment was assessed by two investigators in consensus (SA, KK) for each time point separately. At time of second MRI the investigators were blinded to the IURC defined response of the patients. MRI response was assessed separately for diffuse and focal infiltration and for the combination of both patterns. MRI response according to the change in the number of FL was defined as focal complete remission (fCR) indicating total disappearance of FL, focal partial remission (fPR) being defined as reduction in the number of FL of 50% or more, focal stable disease (fSD) as reduction of less than 50% of the number of FL or no change and focal progressive disease (fPD) as any increase in number of FL after therapy. For diffuse infiltration, dCR was defined as total disappearance of diffuse infiltration. If diffuse infiltration represented by bone marrow cellularity in MRI was reduced to any degree after therapy but was still detectable in MRI compared to a normal bone marrow signal, it was defined as dPR. Constancy of diffuse infiltration was defined as dSD and increase in diffuse infiltration as dPD.
To analyse association of IURC response and combined focal and diffuse MRI response, IURC response was aggregated into 'response' (seroPR or better), 'stable disease' (seroSD) and 'progressive disease' (seroPD). Focal and diffuse MRI assessments were also combined ('overall MRI response') into 'response' (dPR or better; fPR or better or response in both categories), 'stable' (fSD and dSD) and 'progressive' (fPD and/ or dPD).
Statistical analysis
Agreement between MRI response and IURC response were assessed with the weighted Cohen's Kappa coefficient using Fleiss-Cohen weights including 95% confidence interval. Fisher's exact test was used to compare response distribution between treatments. Log-rank test was used to determine prognostic impact of number of FL (0; 1-10; 11-20; >20) on survival, distribution of survival times was estimated with the Kaplan-Meier method. Overall survival was defined as time from second MRI to death from any cause and progression free survival as time from second MRI to progression of disease or death whichever occurred first. Patients being seroPD at second MRI were excluded for PFS. All tests were two-sided, pvalues below 0.05 were considered statistically significant. All analyses were carried out with the statistical software R 2.13.1.
Results and Discussion
Patient cohort and response to treatment:
MRI gains increasing significance in the diagnostic work-up of patients with monoclonal plasma cell disease (13) because this technique has been demonstrated to have a higher sensitivity for the detection of bone marrow infiltration by myeloma cells compared to radiological skeletal survey and computed tomography (6, 14) .
However, few is known about the changes seen in MRI after systemic treatment of Kaplan-Meier plots for overall survival according to the number of FL at first and second MRI are shown in Figure 1 . In addition, the number of FL at second MRI was of prognostic significance for progression free survival (p=0.10 and p=0.03 for first and second MRI, respectively). For the previously reported cut-off of 0-7 versus >7
FL at first MRI (8) we found a borderline significance for PFS and OAS (p=0.06 and p=0.04, respectively).
Interestingly, in our study the number of FL at second MRI showed a significant prognostic effect while that at baseline did not. Hypothetically, the persistence of changes in MRI identifies a subgroup of patients in whom the treatment response of the disease is weaker or maybe slower reflected in a higher residual tumour mass. demonstrated that PET-CT derived parameters are sensitive to treatment response and that they have prognostic significance both at first diagnosis and after ASCT (17) .
However, the availability of PET-CT scanners is still not sufficient and the examination is very expensive because tracers have to be manufactured for each patient. Furthermore, especially if multiple follow-up examinations are necessary the irradiation dose becomes an issue. Compared to that, MRI scanners even with the option of whole body imaging are becoming more and more available having the additional advantages of absent necessity of irradiation and no need of a contrast medium. The sensitivity and specificity of both techniques to detect FL of myeloma in the bone marrow is comparable with a slight benefit for MRI in previous studies (21, 22 
Supplementary data
Time span between first and second MRI:
The time span between first and second MRI varied between 6 and 45 months in our retrospective cohort, however, the time interval itself was not a prognostic factor based on Cox regression models.
Reasons for relapse:
Concerning relapse the following reasons were reported and led to initiation of treatment further on: rise in M-protein in 36 patients (72%), new soft tissue tumour in 5 patients (10%), progressive bone disease in 4 patients (8%), decrease in haemoglobin levels in 2 patients (4%) and variegated reasons in 3 patients (meningeosis, hyposecretory progression, increasing pain).
